60例首发精神分裂症的临床研究

The efficacy of quetiapine in treatment of first-onset schizophrenia

目的:评价喹硫平治疗首发精神分裂症的疗效和安全性。方法:60例首发精神分裂症患者,30例服用喹硫平50～600mg·d^(-1),30例服用氯氮平50～550mg·d^(-1),2组疗程均为8周。采用阳性症状与阴性症状量表(PANSS)和不良反应症状量表(TESS),在治疗前及治疗后第1,2,4,6,8周末分别评定疗效及不良反应。结果:喹硫平与氯氮平组有效率分别为86.7％和80％,显效率分别为76.7％和66.7％。喹硫平起效时间为2周,而在改善阴性症状方面优于氯氮平,其不良反应发生率和严重程度较氯氮平明显少而轻。结论:喹硫平治疗首发精神分裂症疗效好、起效较快,患者服药依从性良好。

Objectives:To study the efficacy and safety of quetiapine. Methods:60 patients with first-onset of schizophrenia were equally divided to receive quetiapine 50 - 600mg · d-1 for 8 weeks, or clozapine 50- 550mg·d-1 for 8 weeks. The efficacy and ADRs were evaluated by PANSS(positive and negative symptom scales) and TESS(treatment emergent symptom scales) respectively. Results: The effective rate of quetiapine and clozapine were 86. 7% and 80% respectively. The onset of action for quetiapine was 2 weeks and the incidence and severity of ADRs for quetiapine were obviously fewer than those of clozapine. Conclusions:The efficacy and safety of quetiapine is better than those of clozapine in treatment of schizophrenia. The onset of action and compliance for the former are also superior to that of the latter.